Business
PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order
Company Advances Next-generation Patented MDMA Toward Patient Dosing in 2026TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) ("PharmAla" or the "Company"), a global leader in the research, development and manufacturing of MDMA and next-generation MDXX class molecules, today responded to the Executive Order signed on April 18, 2026 by the President of the United States, which directs the U.S. Food and Drug Administration ("FDA") and the U.S. Dru
About this update from Pharmala Biotech Holdings, Inc.
[{"type":"image","alt":"PharmAla Biotech","displaySize":"","headline":null,"caption":"PharmAla Biotech","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":167,"url":"https://media.zenfs.com/en/globenewswire.com/cb13b9b085f29f720752eaaea7cf9866"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vib9fcPnFLdmeoNisIg5fg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNA--/https://media.zenfs.com/en/globenewswire.com/cb13b9b085f29f720752eaaea7cf9866","width":300,"height":167}},"lazy":false},{"type":"text","content":"Company Advances Next-generation Patented MDMA Toward Patient Dosing in 2026","length":76,"tagName":"p"},{"type":"text","content":"TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) ("PharmAla" or the "Company"), a global leader in the research, development and manufacturing of MDMA and next-generation MDXX class molecules, today responded to the Executive Order signed on April 18, 2026 by the President of the United States, which directs the U.S. Food and Drug Administration ("FDA") and the U.S. Drug Enforcement Administration ("DEA") to establish a pathway for eligible patients to access investigational psychedelic drugs, and directs the FDA Commissioner to issue National Priority Vouchers to appropriate psychedelic drugs that have received Breakthrough Therapy designation.","length":745,"tagName":"p","attribs":{}},{"type":"text","content":"Positioned and Ready to Supply the U.S. Expanded Access Pathway","length":63,"tagName":"p","attribs":{}},{"type":"text","content":"PharmAla is fully positioned and operationally ready to supply the U.S. Expanded Access pathway contemplated by the Executive Order. PharmAla’s LaNeo™ MDMA is already present in the United States and is actively being supplied into several U.S. clinical trials, including trials sponsored by and conducted within the U.S. Department of Veterans Affairs (VA) and the U.S. Defense Health Agency (DHA). PharmAla’s supply chain, quality systems, and regulatory filings are in place to scale rapidly in response to any increase in U.S. demand generated by the Executive Order.","length":571,"tagName":"p","attribs":{}},{"type":"text","content":"“The Executive Order signed this weekend marks an important inflection point for U.S. patients, and for our sector,” said Nicholas Kadysh,...